{
  "main_header": {
    "sid": 156274,
    "name": "Natco Pharma",
    "stock_name": "Natco Pharma",
    "full_name": "Natco Pharma Ltd.",
    "name_url": "stocks-analysis/natco-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "853.40",
    "chg": 29.9,
    "chgp": "3.63%",
    "dir": 1,
    "prev_price": "823.50",
    "mcapval": "15,264.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524816,
    "symbol": "NATCOPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE987B01026",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "6.18 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/natco-pharma-156274-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [],
    "total": 0,
    "sid": "156274",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/natco-pharma-156274"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "02-Feb-2026",
      "details": "Intimation of Q3FY26 Un-audited Financial Results Earnings Call",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "30-Jan-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And Period Ended 31St December 2025 And Declaration Of 3Rd Interim Dividend If Any For FY 2025-26",
      "datetime": "28-Jan-2026",
      "details": "Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve the unaudited Financial Results for the quarter and period ended 31st December 2025 and declaration of 3rd Interim Dividend if any for FY 2025-26",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has declared <strong>75%</strong> dividend, ex-date: 20 Nov 25",
          "dt": "2025-11-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has announced <strong>2:10</strong> stock split, ex-date: 26 Nov 15",
          "dt": "2015-11-26",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News